Quick Answer
Theriva Biologics, Inc. reported Research And Development Expense of $8.60 million for the year ending 2025.
- Theriva Biologics, Inc. showed a decrease of -28.5% in Research And Development Expense from 2024 to 2025.
- This data is from Theriva Biologics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2010 to 2025), Theriva Biologics, Inc.'s Research And Development Expense has grown by 444.6%.
- Historical annual values: Fiscal year 2025: $8.60 million | Fiscal year 2024: $12.03 million | Fiscal year 2023: $14.31 million | Fiscal year 2022: $11.72 million | Fiscal year 2021: $7.80 million | Fiscal year 2020: $5.13 million | Fiscal year 2019: $11.08 million | Fiscal year 2018: $11.84 million | Fiscal year 2018: $198.0 thousand | Fiscal year 2017: $18.78 million | Fiscal year 2016: $29.11 million | Fiscal year 2015: $32.91 million | Fiscal year 2014: $14.49 million | Fiscal year 2013: $6.51 million | Fiscal year 2012: $12.29 million | Fiscal year 2011: $3.34 million | Fiscal year 2010: $1.58 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: